Details phase 3 trials COVID-19 vaccine candidates

	AstraZeneca	Moderna	Pfizer/BioNtech	Janssen	Sanofi	CureVac	
Vaccine	AZD1222 $5x10^{10}$ vp	mRNA-1273 100 ug	BNT162b2 RNA 30ug	Ad26.COV2.S 5×10^{10} vp	preS dTM 5 ug	cVnCoV	
Platform	Viral vector	mRNA	mRNA	Viral Vector	Protein subunit	mRNA	
Control	saline	saline	saline	saline			
administration	im	im	im	im	im	im	
Number of participants	Vaccine: 20.000 Control:10.000	Vaccine: 15.000 Control 15.000	Vaccine: 21,999 Control: 21,999	Vaccine: 30.000 Control: 30.000	30-35.000		
Age groups	>18 yrs: 18-65 ≥ 65 (at least 25% of total group)	>18 yrs: ≥ 65, <65 at risk <65 not at risk 25-40% in 2 risk groups	≥16 years: 16-55 yrs >55, at least 40% of total	≥18 - <60 years ≥60 years min 30%. (@20% 18-40 yrs) incl. with comorbidities	>18 years incl. elderly and co-morbidities		
Number of vaccine doses	2 (D1, D29)	2 (D1, D29)	2 (D1, D22)	1	1		
Blood collection	Day 1, 15, 43	Day 1, 29, 57, 209, 394, 759	Day 1, 8, 22, 29, 36. Month 6, 12, 24 post dose2	Day 1, 29, 71, Month 6, 12, 18, 24			
Follow-up	2 years	2 years	2 years	2 years + 1 month			
Primary objective	- VE for prevention of COVID-19, -safety and tolerability	-VE to prevent COVID-19 -safety and reactogenicity	VE at least 7 days after dose 2.	-VE prevention moderate, severe COVID -safety			
Primary endpoint	SARS2 PCR 150 events in not seropositive participants	SARS2 PCR 151 events in not seropositive participants	SARS2 PCR 164 events in not seropositive participants	SARS2 PCR 154 events in not seropositive participants			

	baseline. For VE 60% -(S)AEs	baseline. For VE 60% -(S)AEs	baseline. For VE 60% -(S)AEs	baseline, VE60% -(S)EAs			
Secondary objective	-Prevention of infection -VE different case definitions incl severe COVID	-VE severe COVID, -VE serologically confirmed COVID -immunogenicity	-immunogenicity 360 participants	-prevention infection and mild COVID-19 -immunogenicity			
Secondary endpoint	-seroconversion ab against N -symptoms -b-ab S -Neut ab	Serum bAb levels against SARS-CoV-2 S-, N-protein by ligand-binding assay, nAb		-binding Ab ELISA -Neutr ab			
Interim analysis efficacy	1, after 75 cases with VE 70-75%	2, after 53 and 106 cases with VE >=72%	4, first after 32 cases if VE>=77%	Set of 4 predefined criteria			
First indication VE data available	End Dec 2020	End nov 2020	End Oct 2020				